Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Сахарный диабет 2 типа у детей

Список литературы

  1. Дедов И.И., Кураева Т.Л., Петеркова В.А. Сахарный диабет у детей и подростков. Москва: ГЭОТАР-Медиа, 2013. 271 p.
  2. Петеркова В.А., Кураева Т.Л., Еремина И.А. Особенности диабета типа 2 у детей и подростков // Сахарный диабет типа 2: от теории к практике. Под редакцией академика РАН И.И. Дедова, члена-корреспондента РАН М.В. Шестаковой. Москва: ООО «Медицинское информационное агентство», 2016.
  3. Dubinina I.A. et al. Studying progression from glucose intolerance to type 2 diabetes in obese children // Diabetes Metab. Syndr. Clin. Res. Rev. 2014. Vol. 8, № 3. P. 133–137.
  4. Кураева Т.Л. et al. Проблемы диагностики и терапии сахарного диабета 2 типа у детей и подростков // Материалы V Городской научно-практическая конференции «Эндокринологические аспекты в педиатрии». Москва, 2011. P. 26–33.
  5. Александрова Г.А. et al. Общая заболеваемость детского населения России (0 – 14 лет) в 2019 году. Статистические материалы. Часть VI. Москва: Департамент мониторинга, анализа и стратегического развития здравоохранения Минздрава России, ФГБУ «ЦНИИОИЗ» Минздрава России, 2020.
  6. Александрова Г.А. et al. Заболеваемость детского населения России (0 – 14 лет) в 2019 году с диагнозом, установленным впервые в жизни. Статистические материалы. Часть V. Москва: Департамент мониторинга, анализа и стратегического развития здравоохранения Минздрава России, ФГБУ «ЦНИИОИЗ» Минздрава России, 2020.
  7. Александрова Г.А. et al. Заболеваемость детского населения России (15 – 17 лет) в 2019 году с диагнозом, установленным впервые в жизни. Статистические материалы. Часть IX. Москва: Департамент мониторинга, анализа и стратегического развития здравоохранения Минздрава России, ФГБУ «ЦНИИОИЗ» Минздрава России, 2020.
  8. Александрова Г.А. et al. Общая заболеваемость детского населения России (15 – 17 лет) в 2019 году. Статистические материалы. Часть Х. Москва: Департамент мониторинга, анализа и стратегического развития здравоохранения Минздрава России, ФГБУ «ЦНИИОИЗ» Минздрава России, 2020.
  9. Дедов И.И., Шестакова М.В., Викулова О.К. Эпидемиология сахарного диабета в Российской Федерации: клинико-статистический анализ по данным Федерального регистра сахарного диабета. 2017. Vol. 1, № 20. P. 13–41.
  10. Дедов И.И. et al. Сахарный диабет у детей и подростков по данным Федерального регистра Российской Федерации: динамика основных эпидемиологических характеристик за 2013-2016 гг. // Сахарный Диабет. 2017. Vol. 20, № 6. P. 392–402.
  11. Dabelea D. et al. Prevalence of Type 1 and Type 2 Diabetes Among Children and Adolescents From 2001 to 2009 // JAMA. 2014. Vol. 311, № 17. P. 1778.
  12. Libman I. et al. ISPAD Clinical Practice Consensus Guidelines 2022: Definition, epidemiology, and classification of diabetes in children and adolescents // Pediatr. Diabetes. 2022. Vol. 23, № 8. P. 1160–1174.
  13. Dabelea D. et al. Etiological Approach to Characterization of Diabetes Type: The SEARCH for Diabetes in Youth Study // Diabetes Care. 2011. Vol. 34, № 7. P. 1628–1633.
  14. Eremina I.A. et al. Clinical polymorphism of type 2 diabetes in children — the first study in Russia // Probl. Endocrinol. 2015. Vol. 61, № 6. P. 10–16.
  15. Mayer-Davis E.J. et al. ISPAD Clinical Practice Consensus Guidelines 2018: Definition, epidemiology, and classification of diabetes in children and adolescents // Pediatr. Diabetes. 2018. Vol. 19. P. 7–19.
  16. American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2021 // Diabetes Care. 2021. Vol. 44, № Supplement 1. P. S15–S33.
  17. World Health Organization, International Diabetes Federation. Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: report of a WHO/IDF consultation. 2006.
  18. Sabin M.A. Type 2 diabetes in children: Type 2 diabetes in children // Clin. Obes. 2013. Vol. 3, № 3–4. P. 112–116.
  19. Klingensmith G.J. et al. The Presence of GAD and IA-2 Antibodies in Youth With a Type 2 Diabetes Phenotype: Results from the TODAY study // Diabetes Care. 2010. Vol. 33, № 9. P. 1970–1975.
  20. Felton J.L. et al. Islet autoantibodies as precision diagnostic tools to characterize heterogeneity in type 1 diabetes: a systematic review // Commun. Med. 2024. Vol. 4, № 1. P. 66.
  21. Zeitler P. et al. ISPAD Clinical Practice Consensus Guidelines 2018: Type 2 diabetes mellitus in youth // Pediatr. Diabetes. 2018. Vol. 19. P. 28–46.
  22. Petitti D.B. et al. Glycemic Control in Youth with Diabetes: The SEARCH for Diabetes in Youth Study // J. Pediatr. 2009. Vol. 155, № 5. P. 668-672.e3.
  23. Zeitler P. et al. HbA 1c After a Short Period of Monotherapy With Metformin Identifies Durable Glycemic Control Among Adolescents With Type 2 Diabetes // Diabetes Care. 2015. Vol. 38, № 12. P. 2285–2292.
  24. American Diabetes Association. 8. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2018 // Diabetes Care. 2018. Vol. 41, № Supplement 1. P. S73–S85.
  25. Еремина И.А., Кураева Т.Л. Метформин в лечении сахарного диабета 2-го типа у детей и подростков // Проблемы эндокринологии. 2013. № 1. P. 8–13.
  26. Jones K.L. et al. Effect of Metformin in Pediatric Patients With Type 2 Diabetes: A randomized controlled trial // Diabetes Care. 2002. Vol. 25, № 1. P. 89–94.
  27. TODAY Study Group et al. A clinical trial to maintain glycemic control in youth with type 2 diabetes // N. Engl. J. Med. 2012. Vol. 366, № 24. P. 2247–2256.
  28. Fath M. et al. Faster-acting insulin aspart provides faster onset and greater early exposure vs insulin aspart in children and adolescents with type 1 diabetes mellitus: FATH et al . // Pediatr. Diabetes. 2017. Vol. 18, № 8. P. 903–910.
  29. Bode B.W. et al. Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec, in Children and Adolescents With Type 1 Diabetes: The onset 7 Trial // Diabetes Care. 2019. Vol. 42, № 7. P. 1255–1262.
  30. Battelino T. et al. Efficacy and safety of a fixed combination of insulin degludec/insulin aspart in children and adolescents with type 1 diabetes: A randomized trial // Pediatr. Diabetes. 2018. Vol. 19, № 7. P. 1263–1270.
  31. Thalange N. et al. Insulin degludec in combination with bolus insulin aspart is safe and effective in children and adolescents with type 1 diabetes: IDeg effective and safe in pediatric T1D // Pediatr. Diabetes. 2015. Vol. 16, № 3. P. 164–176.
  32. Danne T. et al. Pharmacokinetics, prandial glucose control, and safety of insulin glulisine in children and adolescents with type 1 diabetes // Diabetes Care. 2005. Vol. 28, № 9. P. 2100–2105.
  33. Philotheou A. et al. Comparable Efficacy and Safety of Insulin Glulisine and Insulin Lispro When Given as Part of a Basal–Bolus Insulin Regimen in a 26-Week Trial in Pediatric Patients with Type 1 Diabetes // Diabetes Technol. Ther. 2011. Vol. 13, № 3. P. 327–334.
  34. Holcombe J.H. et al. Comparison of insulin lispro with regular human insulin for the treatment of type 1 diabetes in adolescents // Clin. Ther. 2002. Vol. 24, № 4. P. 629–638.
  35. Tupola S. et al. Post-prandial insulin lispro vs. human regular insulin in prepubertal children with Type 1 diabetes mellitus // Diabet. Med. J. Br. Diabet. Assoc. 2001. Vol. 18, № 8. P. 654–658.
  36. Deeb L.C. et al. Insulin Lispro Lowers Postprandial Glucose in Prepubertal Children With Diabetes // PEDIATRICS. 2001. Vol. 108, № 5. P. 1175–1179.
  37. Liu M. et al. A randomised, open-labelstudy of insulin glargine or neutral protamine Hagedorn insulin in Chinese paediatric patients with type 1 diabetes mellitus // BMC Endocr. Disord. 2016. Vol. 16, № 1. P. 67.
  38. Schober E. et al. Comparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetes mellitus // J. Pediatr. Endocrinol. Metab. JPEM. 2002. Vol. 15, № 4. P. 369–376.
  39. Robertson K.J. et al. Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetes // Diabet. Med. J. Br. Diabet. Assoc. 2007. Vol. 24, № 1. P. 27–34.
  40. Thalange N. et al. The rate of hyperglycemia and ketosis with insulin degludec‐based treatment compared with insulin detemir in pediatric patients with type 1 diabetes: An analysis of data from two randomized trials // Pediatr. Diabetes. 2019. Vol. 20, № 3. P. 314–320.
  41. Danne T. et al. Insulin detemir is characterized by a consistent pharmacokinetic profile across age-groups in children, adolescents, and adults with type 1 diabetes // Diabetes Care. 2003. Vol. 26, № 11. P. 3087–3092.
  42. Danne T. et al. Efficacy and Safety of Insulin Glargine 300 Units/mL (Gla-300) Versus Insulin Glargine 100 Units/mL (Gla-100) in Children and Adolescents (6-17 years) With Type 1 Diabetes: Results of the EDITION JUNIOR Randomized Controlled Trial // Diabetes Care. 2020. Vol. 43, № 7. P. 1512–1519.
  43. Predieri B. et al. Switching From Glargine to Degludec: The Effect on Metabolic Control and Safety During 1-Year of Real Clinical Practice in Children and Adolescents With Type 1 Diabetes // Front. Endocrinol. 2018. Vol. 9. P. 462.
  44. Дедов И.И. et al. Проект рекомендаций Российской ассоциации эндокринологов по применению биосимиляров инсулина. 2021. Vol. 24, № 1. P. 76–79.
  45. Arslanian S. et al. Evaluation and Management of Youth-Onset Type 2 Diabetes: A Position Statement by the American Diabetes Association // Diabetes Care. 2018. Vol. 41, № 12. P. 2648–2668.
  46. Tamborlane W.V. et al. Liraglutide in Children and Adolescents with Type 2 Diabetes // N. Engl. J. Med. 2019. Vol. 381, № 7. P. 637–646.
  47. Frid A.H. et al. New Insulin Delivery Recommendations // Mayo Clin. Proc. 2016. Vol. 91, № 9. P. 1231–1255.
  48. Майоров А.Ю. et al. Техника инъекций и инфузии при лечении сахарного диабета. Методическое руководство. Москва: ООО «АРТИНФО», 2018. 64 p.
  49. Smart C.E. et al. ISPAD Clinical Practice Consensus Guidelines 2018: Nutritional management in children and adolescents with diabetes // Pediatr. Diabetes. 2018. Vol. 19. P. 136–154.
  50. American Diabetes Association. 4. Lifestyle Management: Standards of Medical Care in Diabetes—2018 // Diabetes Care. 2018. Vol. 41, № Supplement 1. P. S38–S50.
  51. Barlow S.E. Expert Committee Recommendations Regarding the Prevention, Assessment, and Treatment of Child and Adolescent Overweight and Obesity: Summary Report // Pediatrics. 2007. Vol. 120, № Supplement 4. P. S164–S192.
  52. Lien A.S.-Y. et al. A Systematic Review and Meta-Analysis of the Effect of Lifestyle Modification on Metabolic Control in Overweight Children // Evid. Based Complement. Alternat. Med. 2017. Vol. 2017. P. 1–12.
  53. Dhuper S., Buddhe S., Patel S. Managing Cardiovascular Risk in Overweight Children and Adolescents // Pediatr. Drugs. 2013. Vol. 15, № 3. P. 181–190.
  54. Jensen M.D. et al. 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society // Circulation. 2014. Vol. 129, № 25 suppl 2. P. S102–S138.
  55. Chahal H. et al. Availability and night-time use of electronic entertainment and communication devices are associated with short sleep duration and obesity among Canadian children: EECD use and obesity among children // Pediatr. Obes. 2013. Vol. 8, № 1. P. 42–51.
  56. Lane A., Harrison M., Murphy N. Screen Time Increases Risk of Overweight and Obesity in Active and Inactive 9-Year-Old Irish Children: A Cross Sectional Analysis // J. Phys. Act. Health. 2014. Vol. 11, № 5. P. 985–991.
  57. Adolfsson P. et al. ISPAD Clinical Practice Consensus Guidelines 2018: Exercise in children and adolescents with diabetes // Pediatr. Diabetes. 2018. Vol. 19. P. 205–226.
  58. Glazier R.H. et al. A Systematic Review of Interventions to Improve Diabetes Care in Socially Disadvantaged Populations // Diabetes Care. 2006. Vol. 29, № 7. P. 1675–1688.
  59. Nadeau K.J. et al. Youth-Onset Type 2 Diabetes Consensus Report: Current Status, Challenges, and Priorities // Diabetes Care. 2016. Vol. 39, № 9. P. 1635–1642.
  60. Ibáñez L. et al. Exaggerated Adrenarche and Hyperinsulinism in Adolescent Girls Born Small for Gestational Age // J. Clin. Endocrinol. Metab. 1999. Vol. 84, № 12. P. 4739–4741.
  61. Dabelea D., Crume T. Maternal Environment and the Transgenerational Cycle of Obesity and Diabetes // Diabetes. 2011. Vol. 60, № 7. P. 1849–1855.
  62. Yokoyama H. et al. Higher incidence of diabetic nephropathy in type 2 than in type 1 diabetes in early-onset diabetes in Japan // Kidney Int. 2000. Vol. 58, № 1. P. 302–311.
  63. Stevens P.E., Levin A., Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline // Ann. Intern. Med. 2013. Vol. 158, № 11. P. 825–830.
  64. Schwartz G.J. et al. New equations to estimate GFR in children with CKD // J. Am. Soc. Nephrol. JASN. 2009. Vol. 20, № 3. P. 629–637.
  65. Schwartz G.J., Work D.F. Measurement and estimation of GFR in children and adolescents // Clin. J. Am. Soc. Nephrol. CJASN. 2009. Vol. 4, № 11. P. 1832–1843.
  66. Copeland K.C. et al. Characteristics of Adolescents and Youth with Recent-Onset Type 2 Diabetes: The TODAY Cohort at Baseline // J. Clin. Endocrinol. Metab. 2011. Vol. 96, № 1. P. 159–167.
  67. TODAY Study Group. Rapid Rise in Hypertension and Nephropathy in Youth With Type 2 Diabetes: The TODAY clinical trial // Diabetes Care. 2013. Vol. 36, № 6. P. 1735–1741.
  68. Lewis E.J. et al. The Effect of Angiotensin-Converting-Enzyme Inhibition on Diabetic Nephropathy // N. Engl. J. Med. 1993. Vol. 329, № 20. P. 1456–1462.
  69. Strippoli G.F.M. et al. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review // BMJ. 2004. Vol. 329, № 7470. P. 828.
  70. Lv J. et al. Antihypertensive agents for preventing diabetic kidney disease // Cochrane Database Syst. Rev. / ed. Cochrane Kidney and Transplant Group. 2012.
  71. Strippoli G.F. et al. Antihypertensive agents for preventing diabetic kidney disease // Cochrane Database of Systematic Reviews / ed. The Cochrane Collaboration. Chichester, UK: John Wiley & Sons, Ltd, 2005. P. CD004136.pub2.
  72. Wu H.-Y. et al. Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis // BMJ. 2013. Vol. 347, № oct24 2. P. f6008–f6008.
  73. Barkai L, Soós A, Vámosi I. The effect of captopril therapy on the degree of microalbuminuria in diabetic children and adolescents with incipient nephropathy // Orv Hetil. 1996. Vol. 137, № 46. P. 2565–2568.
  74. American Diabetes Association. 10. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes—2018 // Diabetes Care. 2018. Vol. 41, № Supplement 1. P. S105–S118.
  75. Wong J. et al. Timing Is Everything: Age of Onset Influences Long-Term Retinopathy Risk in Type 2 Diabetes, Independent of Traditional Risk Factors // Diabetes Care. 2008. Vol. 31, № 10. P. 1985–1990.
  76. Constantino M.I. et al. Long-Term Complications and Mortality in Young-Onset Diabetes: Type 2 diabetes is more hazardous and lethal than type 1 diabetes // Diabetes Care. 2013. Vol. 36, № 12. P. 3863–3869.
  77. Donaghue K.C. et al. ISPAD Clinical Practice Consensus Guidelines 2018: Microvascular and macrovascular complications in children and adolescents // Pediatr. Diabetes. 2018. Vol. 19. P. 262–274.
  78. Martinez-Zapata M.J. et al. Anti-vascular endothelial growth factor for proliferative diabetic retinopathy // Cochrane Database Syst. Rev. / ed. Cochrane Eyes and Vision Group. 2014.
  79. Simunovic M.P., Maberley D.A.L. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR PROLIFERATIVE DIABETIC RETINOPATHY: A Systematic Review and Meta-Analysis // Retina. 2015. Vol. 35, № 10. P. 1931–1942.
  80. TODAY Study Group. Retinopathy in Youth With Type 2 Diabetes Participating in the TODAY Clinical Trial // Diabetes Care. 2013. Vol. 36, № 6. P. 1772–1774.
  81. Rodriguez B.L. et al. Prevalence of cardiovascular disease risk factors in U.S. children and adolescents with diabetes: the SEARCH for diabetes in youth study // Diabetes Care. 2006. Vol. 29, № 8. P. 1891–1896.
  82. Еремина И.А. et al. Кардиоваскулярная форма автономной нейропатии у подростков с сахарным диабетом 2 типа // Проблемы Эндокринологии. 2014. Vol. 60, № 5. P. 15–21.
  83. Maffi P., Secchi A. The Burden of Diabetes: Emerging Data // Developments in Ophthalmology / ed. Bandello F. et al. S. Karger AG, 2017. Vol. 60. P. 1–5.
  84. Jaiswal M. et al. Cardiovascular autonomic neuropathy in adolescents and young adults with type 1 and type 2 diabetes: The SEARCH for Diabetes in Youth Cohort Study // Pediatr. Diabetes. 2018.
  85. Copeland K.C. et al. Management of Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) in Children and Adolescents // PEDIATRICS. 2013. Vol. 131, № 2. P. 364–382.
  86. EXPERT PANEL ON INTEGRATED GUIDELINES FOR CARDIOVASCULAR HEALTH AND RISK REDUCTION IN CHILDREN AND ADOLESCENTS. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: Summary Report // PEDIATRICS. 2011. Vol. 128, № Supplement. P. S213–S256.
  87. TODAY Study Group. Lipid and Inflammatory Cardiovascular Risk Worsens Over 3 Years in Youth With Type 2 Diabetes: The TODAY clinical trial // Diabetes Care. 2013. Vol. 36, № 6. P. 1758–1764.
  88. Batisky D.L. What Is the Optimal First-Line Agent in Children Requiring Antihypertensive Medication? // Curr. Hypertens. Rep. 2012. Vol. 14, № 6. P. 603–607.
  89. Blowey D.L. Update on the Pharmacologic Treatment of Hypertension in Pediatrics: Update on Pharmacologic Treatment in Pediatrics // J. Clin. Hypertens. 2012. Vol. 14, № 6. P. 383–387.
  90. Legro R.S. et al. Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline // J. Clin. Endocrinol. Metab. 2013. Vol. 98, № 12. P. 4565–4592.
  91. Newton K.P. et al. Prevalence of Prediabetes and Type 2 Diabetes in Children With Nonalcoholic Fatty Liver Disease // JAMA Pediatr. 2016. Vol. 170, № 10. P. e161971.
  92. Nadeau K.J., Klingensmith G., Zeitler P. Type 2 Diabetes in Children is Frequently Associated with Elevated Alanine Aminotransferase: // J. Pediatr. Gastroenterol. Nutr. 2005. Vol. 41, № 1. P. 94–98.
  93. Sundaram S.S., Zeitler P., Nadeau K. The metabolic syndrome and nonalcoholic fatty liver disease in children: // Curr. Opin. Pediatr. 2009. Vol. 21, № 4. P. 529–535.
  94. Reinehr T. et al. Lifestyle intervention in obese children with non-alcoholic fatty liver disease: 2-year follow-up study // Arch. Dis. Child. 2009. Vol. 94, № 6. P. 437–442.
  95. Angulo P. et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis // Hepatology. 1999. Vol. 30, № 6. P. 1356–1362.
  96. Shaw J.E. et al. Sleep-disordered breathing and type 2 diabetes // Diabetes Res. Clin. Pract. 2008. Vol. 81, № 1. P. 2–12.
  97. Foster G.D. et al. Obstructive Sleep Apnea Among Obese Patients With Type 2 Diabetes // Diabetes Care. 2009. Vol. 32, № 6. P. 1017–1019.
  98. Abraham M.B. et al. ISPAD Clinical Practice Consensus Guidelines 2018: Assessment and management of hypoglycemia in children and adolescents with diabetes // Pediatr. Diabetes. 2018. Vol. 19. P. 178–192.
  99. Tinti D., Rabbone I. Mini-doses of glucagon to prevent hypoglycemia in children with type 1 diabetes refusing food: a case series // Acta Diabetol. 2019.

Для продолжения работы требуется Registration
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Table of contents

Данный блок поддерживает скрол*